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Background: Postpartum women need effective contraception. Concerns have been raised that use of progestogen-only contraceptives
(POCs) may affect breastfeeding performance and infant health outcomes.
Objectives: We investigated the clinical outcomes of breastfeeding duration, initiation of supplemental feeding and weaning, as well as
infant outcomes including infant growth, health and development among breastfeeding women using POCs compared with breastfeeding
women not using POCs.
Search strategy: We searched the PubMed database for all articles published from database inception through December 2014.
Selection criteria: We included primary research studies of breastfeeding women of any age or parity who received POCs, including
progestogen-only pills, injectables, implants or hormonal intrauterine devices (IUDs). The main outcomes were breastfeeding performance
(as measured by initiation, continuation, frequency and exclusivity of breastfeeding) and infant health (as measured by growth, development
or adverse health effects).
Results: Forty-nine articles reporting on 47 different studies were identified that investigated the use of POCs in breastfeeding women and
reported clinically relevant outcomes of infant growth, health or breastfeeding performance. Studies ranged from poor to fair methodological
quality and generally failed to show negative effects of the use of POCs on breastfeeding outcomes or on infant growth or development. One
randomized controlled trial (RCT) raises concerns that immediate insertion of the levonorgestrel IUD postpartum may be associated with
poorer breastfeeding performance when compared with delayed insertion, although two other RCTs evaluating early etonogestrel implants
compared with delayed initiation of implants or depot medroxyprogesterone acetate failed to find such an association.
Conclusion: The preponderance of evidence fails to demonstrate adverse breastfeeding outcomes or negative health outcomes in infants such as
restricted growth, health problems or impaired development. Evidence newly added to this review was largely consistent with previous evidence.
©2016Published byElsevier Inc. This is an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords: Lactation; Contraception; Progestogens; Breastfeeding1. Introduction
The benefits of breastfeeding for both women and their
infants are considerable [1–3]. TheWorld Health Organization☆ The findings and conclusions in this report are those of the authors and
do not necessarily represent the official position of the World Health
Organization or US Centers for Disease Control and Prevention.
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sharonphillipsmd@gmail.com (S.J. Phillips).
http://dx.doi.org/10.1016/j.contraception.2015.09.010
0010-7824/© 2016 Published by Elsevier Inc. This is an open access article under th(WHO) recommends infants breastfeed exclusively during the
first months of life [4]. Although women breastfeeding
exclusively and on demand are unlikely to conceive before
6 weeks postpartum, many women discontinue fully breast-
feeding before that time and are at risk of repeat pregnancy [5].
Because birth spacing has demonstrated health benefits for
women and infants, early initiation of contraception in the
postpartum period may improve outcomes.
Progestogen-only and progesterone contraceptives have
been in use for years; however, their dosages and
formulations have changed over time. Methods availablee CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Included studies
Author,
year,
source of support
Study design,
location,
population
Interventions Outcomes,
follow-up duration
Results Strengths/weaknesses Quality grading/
key question
Kamal, 1969 [30]
Not stated
Newly identified
Nonrandomized clinical
trial
Egypt
N=120 PP women
(data available on 50)
6–10 weeks PP:
POP (0.5 mg lynestrenol)
IUD+placebo
2 kinds of COCs, 1 combined
injectable contraceptive (not
reported here)
Allocation not reported
BF performance (age of
supplementation)
Infant growth (growth
curve, percent weight
increase)
Follow-up 32 weeks
BF outcomes
–Average age of
supplementation
11.2 weeks POP
group, 15 weeks
placebo (statistics not
reported)
Infant outcomes
–No relation between
growth curve and
method used
Strengths
–Double blinded
Weaknesses
–No statistical analysis
reported for comparisons
of interest
–High, but not clearly
reported, loss to
follow-up
–Number of participants/
group not reported
Level II-1
Poor
Key Question 1
Kamal, 1970 [43]
Not stated
Nonrandomized
clinical trial
Egypt
N=40 primiparous and
multiparous women,
ages 20–37 years
2 days PP:
10=placebo
10=POP (lynestrenol
500 mcg)
10=COC (results not
presented)
10=ethinyl estradiol (results
not presented)
BF performance (initiation
of lactation)
Infant growth (weight)
Follow-up 14 days
BF outcomes
–Lactation initiation
earlier (3 vs. 5 days)
in POP than placebo
group
Infant outcomes
–Greatest weight
increase in
POP-exposed infants
Strengths:
–Included primiparas
Weaknesses:
–Nonrandomized
–Small sample size
–Short follow-up
–No statistical
comparisons
Level II-1
Poor
Key Question 1
Karim, 1971 [36]
Not stated
Prospective cohort
Egypt
N=331 women after
normal delivery
7 days PP:
68=NET-EN (200 mg)
51=DMPA (150 mg)
100=NH
42 days PP:
57=NET-EN
55=DMPA
BF performance
(supplementation)
Infant growth and health
(weight, physical exam,
dentition, mentality,
walking, radiographs)
Follow-up 18 months
BF outcomes
–No BF
supplementation
reported up to
6 months in any
groups
Infant outcomes
–After 3rd month,
infant weight gain per
month higher in all
POC groups than in
NH controls; weight
gain in hormonal
groups equivalent
–No physical, mental
or radiologic
differences in infants
between groups
Weaknesses:
–Percent follow- up of
infants not reported
–No standardized
techniques to measure
health and specifics of
health outcomes not
reported
Level II-2,
poor
Key Questions 1 and 2
Guiloff et al., 1974 [37]
Population council,
Warner-Lambert
Research Institute
Cohort
Chile
N=696 multiparous
women, ages 16–
40 years
1–2 days PP:
80=DMPA
(250 mg im q 6 months)
30 days PP:
33=DMPA
BF performance (mean
duration of lactation)
Follow-up 12 months
BF outcomes
Mean lactation
duration (presented
as mean months with
95% CI)
Weaknesses:
–Unclear if prospective
or retrospective
–Historical control
–Historical recollection
Level II-2
Poor
Key Question 1
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227
S.J.
P
hillips
et
al.
/
C
ontraception
94
(2016)
226–252
Table 1 (continued)
Author,
year,
source of support
Study design,
location,
population
Interventions Outcomes,
follow-up duration
Results Strengths/weaknesses Quality grading/
key question
Historical control was
composed of the past
lactation history of a
subset of women
enrolled in the study
who were still BF at
30 days
54=Chlormadione acetate
(250 mg im q 3 months)
81=Quingestanol acetate
(300 mcg)
81=IUD
Other participants used
COCs (results not reported
here)
DMPA 1–2 days PP:
6.7 (5.2–8.7)
Historical control: 4.8
(4.1–5.3)
DMPA 30 days PP:
9.3 (6.0–10.0)
Chlormadione acetate
30 days PP:
7.5 months (4.7–9.7)
Quingestanol acetate
30 days PP: 4.2
(2.8–5.6)
IUD 30 days PP: 7.7
(6.8–8.9)
Historical control: 5.3
(4.8–5.8)
of duration of lactation
Giner-Velasquez
et al., 1976 [33]
Not stated
RCT
Mexico
N=20 healthy
women, ages
18–36 years
≤14 h PP:
12=NET (350 mcg)
8=Placebo
BF performance (initiation)
Infant growth (weight)
Follow-up 14 days
BF outcomes
No difference
between groups in BF
initiation (statistics
not reported)
Infant outcomes
No difference
between groups in
weight gain (average
493 g placebo, 441 g
NET, difference not
significant)
Weaknesses:
–Methods poorly described
–Small sample size
–Follow-up and
exclusions not described
Level I,
Poor
Key Question 1
Zanartu et al., 1976 [31]
CEBRE, University
of Chile Medical
School
Newly identified
Prospective cohort
N=406 fully BF
women using DMPA
with at least
18 months follow-up,
173 controls
First 30 days PP:
N=133 DMPA
30–90 days PP:
N=206 DMPA 30–90 days
PP
91–180 days PP:
N=67 DMPA
(DMPA 150 or 250–300 mg)
N=173 no DMPA (and either
received education about BF
or no intervention)
BF performance (exclusive
and partial lactation status at
3, 6, 12, 18 months)
Follow-up 18 months
BF outcomes
3rd month/6th month
PP: 94%/80% DMPA
group fully BF; fewer
in non-DMPA group
(pb.001)
12th/18th month PP:
42%/10% still BF;
fewer in non-DMPA
group (pb.001)
Of those who received
DMPA up to 90 days
PP, 35% still BF at
12 months (vs. 64%
who received after
90 days, no statistics)
Strengths:
–High percentage with
follow-up (406/500 with
at least 18 months
follow-up)
Weaknesses:
–Unclear if non-DMPA
users were using other
hormonal or NH
contraceptives
–No separate analysis by
DMPA dose; minimal
analysis by timing; no
statistical analysis for
indirect comparison
–Wide range in timing of
DMPA administration
Level II-2, Poor
Key Question 1
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–No statistical analyses
Zanartu et al., 1976
[45]
Ayerst
Nonrandomized
clinical trial
Chile
N=100 healthy
women, ages 19–42 years
3rd to 10th week PP:
100=Chlormadione acetate
0.6 mg
173=NH(historical control; some
inert IUD, some no method)
BF performance (duration)
Follow-up 18 months
BF outcomes
At 3 months:
98% Chlormadione
still BF
76% NH still BF
At 6 months:
80% (POP) and 56%
(NH) still BF
At 12 months:
42% (POP) and 0%
(NH) still BF
(pb.001)
Weaknesses:
–Historical control
–Wide variation in
timing of contraceptive
initiation
–Loss to follow-up not
reported
–Statistical analyses not
reported for all outcomes
of interest
Level II-1,
Poor
Key Question 1
Seth et al., 1977 [49]
WHO
Cohort
India
N=50 healthy,
women, ages
20–40 years
6 days PP:
23=Implant (40 mg
norethindrone acetate)
(early)
6 weeks PP:
12=Implant (delayed)
15=NH (Condoms/gel)
BF performance (continued
BF at 8 months,
supplementation rates)
Infant growth (weight)
Follow-up 11 months
BF outcomes
Still BF at 8 months
80% NH, 56.6%
early, 66.6% delayed,
difference not
significant
3 months
supplementation
Early implant 56.4%,
controls 40% (pb.05),
other times, NS
Infant outcomes
No differences between
groups in weight
Weaknesses:
–Small sample size
–Methods poorly
described
–Baseline characteristics
not described
–Percent follow-up not
reported
Level II-2, Poor
Key Questions 1 and 2
Croxatto et al., 1982
[55]
Population Council
and Canadian
International
Development
Research Center
Cohort
Chile
N=439 healthy
women who did not
hold jobs, ages
18–35 years
30–35 days PP:
84=Progesterone pellets
(100 mg)
130=Placebo injectable
125=Cu T200 IUD
BF performance (fully,
partially or not BF at
follow-up visits)
Infant growth (weight)
Infant health (reports of
intercurrent illness)
Follow-up 12 months
BF outcomes
Fully BF: No
significant difference
between groups at 3, 6
or 9 months
BF at 6 months
51.2% progesterone
58.3% IUD
BF at 12 months
10.7% progesterone
17.6% IUD (pb.05)
Infant outcomes
No differences in
infant weight gain
among groups
(4515 g progesterone,
4633 placebo, 4801
IUD, not statistically
significant) or health
(no statistics reported)
Weaknesses:
–Little description of
intercurrent illnesses (or
their assessment)
–High rates of
discontinuation/
termination from study/
loss to follow-up in all
groups
Level II-2, Fair
Key Question 1
Dahlberg, 1982 [32]
No funding
Retrospective cohort
Thailand
Some time in 1st 9 months PP:
210=Some exposure to
Infant growth (weight)
Infant health (incidence of
Infant outcomes
Weight gain
Strengths:
–Subgroup data
Level II-2, Poor
Key Questions 1 and 2
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Table 1 (continued)
Author,
year,
source of support
Study design,
location,
population
Interventions Outcomes,
follow-up duration
Results Strengths/weaknesses Quality grading/
key question
Newly identified N=331 infants born at
Thai hospital between
1977 and 1979
DMPA
121=No exposure to DMPA
infectious diseases leading
to clinic visits)
Follow-up up to 46 months
No difference
between groups at any
time point in
follow-up, regardless
of length of exposure
Health
No difference in
average numbers of
infectious diseases
reported per year
between groups
(although subgroup
who received DMPA
at 2 days PP had 75%
higher incidence than
other groups,
statistics not reported)
presented with different
amounts of DMPA
exposure
Weaknesses:
–Data obtained solely
through record review
–Statistical analysis not
reported
–Analytical methods not
clearly described
–Timing of exposure to
DMPA not clear
–Wide variation in when
DMPA was given PP
Heikkila and
Luukkainen, 1982
[34]
Population Council,
US Agency for
International
Development, Ford
Foundation
RCT (with change to
protocol partway
through trial)
Finland
N=110 women
32–56 days PP:
30=LNG (10 mcg/day IUD)
40=LNG (30 mcg/day IUD)
40=Copper IUD
BF performance (duration,
time to supplementation)
Infant growth (height,
weight)
Infant development (time of
walking, tooth eruption)
Infant health (infectious
diseases)
Follow-up 12 months
BF outcomes
BF continuation
75 days
postinsertion: 79% in
IUD group, 56%
LNG 30 group, pb.05
(results for LNG-10
not reported)
BF continuation
6 months
post inser t ion : no
difference among 3
groups
Median duration of BF
141 days LNG-10;
154 days LNG-30;
197 days Cu-IUD
(difference
significant)
Mean duration: no
significant difference
Supplementation: no
significant difference
Infant outcomes
Growth and
development
No differences in
height, weight, time
Weaknesses:
–Allocation concealment
and randomization
sequence ill-described
–Mid-way through trial,
added lower-dose IUD
and changed allocation
scheme
–Copper IUD group
younger and less parous
–Illnesses not recorded
or assessed systematically
Level I, Poor
Key Question 1
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of walking, tooth
eruption
Health
No differences
between groups in
respiratory/middle
ear infections
West et al., 1983 [44]
Medical Research
Council
Cohort
Scotland
N = 2 2 7 h e a l t h y
women, fully BF
(data available on
203)
Up to 8 weeks PP:
84=Norethisterone 0.35 mg
(76% by week 4)
29=COC
89=NH
BF performance (duration,
supplementation)
BF outcomes:
At 3 months: 62%
POP, 62% NH still BF
At 5 months: 51%
POP, 53% NH still BF
(statistics not reported)
Weaknesses
–Follow-up by postal
survey
–No statistical analysis
–Unclear when methods
were initiated
Level II-2, Poor
Key Question 1
Diaz et al., 1984 [54]
Instituto Bioquinico
Beta, WHO,
International
Development
Research Centre of
Canada, Population
Council
Cohort
Chile
N=653 healthy
women after normal
pregnancy, 18–35 years
30 days PP:
84=Progesterone pellets
(100 mg)
125=Cu T200 IUD
130=Placebo injection
60 days PP:
193=Progesterone pellets
121=Cu T200 IUD
BF performance (exclusivity
at 6 months and
continuation)
Infant growth (weight gain
at 6 months) and health
(how assessed not defined)
Follow-up 6 months
BF outcomes:
No difference in BF
status at 6 months
between those
initiated at 30 or
60 days PP and their
contemporary
controls; however,
those who initiated at
day 60 were more
likely to supplement
at month 6 than those
initiating at day 30
(68% exclusive vs.
53% exclusive,
statistics not reported)
Infant outcomes
Weight gain
No difference
between groups
Health
No negative effects of
progesterone on
infant health
Strengths
–Clear description of
methods and analysis
Weaknesses:
–Women lost to
follow-up or
discontinuing their
method not reported
–Statistical analyses not
presented for outcomes
of interest
–No control for
confounding
–Unclear how infant
health was assessed
Level II-2, Poor
Key Questions 1 and 2
Jimenez et al., 1984
[38]
Upjohn
Retrospective cohort—
follow-up to
unpublished primary
study
Chile
N=270
Women and their
children exposed to
contraception during
lactation,
3–6 years prior
2nd month PP:
128=DMPA (150 mg q
3 months)
142=NH
BF performance (reported
duration of lactation)
Infant growth (weight, arm
circumference, head
circumference)
Infant health (respiratory
infections, diarrheal disease,
hospital admissions, mortality)
Infant development
(standardized physical exam,
interview, record review and
psychomotor scale)
BF outcomes:
Median lactation
duration: 21 months
DMPA vs. 13 months
NH (pb.05)
Infant outcomes
Growth
No difference
between groups in
height; weight
different between
groups but no
Weaknesses:
–Primary study not
published
–Some outcomes relied
on retrospective
self-report
–Groups dissimilar
(mothers in DMPA
group older, of higher
parity)
Level II-2, Poor
Key Question 1
(continued on next page)
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Table 1 (continued)
Author,
year,
source of support
Study design,
location,
population
Interventions Outcomes,
follow-up duration
Results Strengths/weaknesses Quality grading/
key question
difference when
adjusted for
confounders
Health
1 death in control
group (accidental), 0
in DMPA group
Development
No differences
between groups in
psychomotor
development,
milestones, health
problems, infant
height or physical
exam
Tankeyoon et al.,
1984 [57]
WHO
Prospective cohort
with nested RCT
Hungary
Thailand
N=341 experienced
BF women, ages 20–
35 years, parity 2–4,
after healthy term
delivery
6 weeks PP (±3 days):
59=DMPA
1 1 1 = N H ( b a r r i e r s ,
sterilization, IUD)
Pill-users (randomized):
85=POP
86=COC ( re su l t s no t
reported here)
BF performance (use of
comp l emen t a r y f ood ,
discontinuation due to
perceived inadequate milk
supply)
Infant growth (weight,
length, arm circumference)
Follow-up 24 weeks
BF outcomes:
No differences in
complementary
feeding or
discontinuation of BF
between groups
Infant outcomes
No differences in
mean weight or rate of
growth between
contraceptive groups
Strengths:
–Multicultural and
multicenter with nested
double blinded RCT
Weaknesses:
–No power calculation
–No details of method
switching/discontinuation
–No attempt to control
analysis for confounders
Level II-2, Poor
Key Question 1
Abdulla et al., 1985
[66]
Rockefeller
Foundation
Cohort
Egypt
N=20 healthy women
after singleton, term
delivery (mean age
29 years)
30–39 days PP:
10=LNG implant
10=Barriers/nothing
Infant health (occurrence of
significant illnesses; serum
IgA, IgG, IgM)
Follow-up 6 months
Infant outcomes
No infants had
significant illnesses
No significant
differences between
groups in infant
serum
immunoglobulins
Weaknesses:
–Selection and
assessment procedures
not specified
–Small sample size with
no power calculations
–Percent follow-up not
reported
Level II-2, Poor
Key Question 1
Shaaban et al., 1985
[50]
Rockefeller
Foundation
Cohort
Egypt
N=150 healthy,
multiparous,
BF-experienced
women (mean age
29 years) after
normal, term delivery
30–42 days PP:
50=LNG implant
50=Cu T380 IUD
50=Barriers/nothing
BF performance (frequency,
supplementation)
Infant growth (weight,
length)
Infant health (illness)
Follow-up 6 months
BF outcomes
No differences in
number BF episodes/
day or number
supplemental feeds
Infant outcomes
Growth
Slower weight gain in
Norplant group to
3 months (but N50%
Weaknesses:
–No adjustment of for
possible confounders
–Differences at baseline
between groups
–Unclear how infant
morbidity was measured
Level II-2, Poor
Key Question 1
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percentile); no
differences at
4–6 months; slower
length increase in
Norplant group from
months 3–6 (but
N50% percentile)
Health
No differences in
infant morbidity
Shikary et al., 1986
[65]
WHO, Population
Council
Cohort
India
N=29 women after
term delivery of male
infants, ages 20–
35 years
4 weeks PP:
9=POP (LNG 30 mcg)
10=LNG implant
10=No method
Infant health (daily 4-h urine
samples tested for FSH, LH,
testosterone)
Follow-up 15 weeks
Infant outcomes
No significant
differences in mean
FSH, LH and
testosterone area
under the curve
between the groups
Weaknesses:
–Small sample size with
no power calculations
–Short follow-up
Level II-2, Fair
Key Question 1
Zacharias et al., 1986
[39]
UpJohn, Ayerst
Prospective cohort
Chile
N=665 women, after
term deliveries
3–6 weeks PP:
143=LAM
109=Cu T IUD (presumably
NH)
228=DMPA
1 8 5 = P O P ( 0 . 6 m g
clogestone acetate)
BF performance (duration)
Infant growth and
development (not specified)
Follow-up of children to a
median age of 4.5 years
BF outcomes
Mean duration:
17 months LAM
21 months IUD
30 DMPA
22 POP (pb.03 for
pairwise comparison
with DMPA)
Infant outcomes
Growth/development
No adverse effects of
progestogens (not
specified)
Strengths:
–Survival analysis
techniques
Weaknesses:
–Measures for growth
and development not
provided
–Statistical comparisons
not performed
–No attempt to control
analysis for confounders
–Baseline differences
between groups
–Infants with “signs of
inadequate nutrition”
discontinued from study
and not reported on
Level II-2, Poor
Key Question 1
Affandi et al., 1986
[67]
Population Council
Cohort
Indonesia
N=120 women
after term, healthy
delivery, planning to
breastfeed
≥6 months
4–6 weeks PP:
60=LNG implant
60=Copper IUD
Infant growth (weight,
length)
Follow-up 6 months
Infant outcomes
Infants in LNG group
gained significantly
more weight than the
IUD group. No
differences in length
between groups
(statistical
comparisons, p values
not provided)
Weaknesses:
–Limited description of
statistical analysis and no
attempt to control for
confounders
–Baseline differences
between groups
–Percent follow-up not
reported
Level II-2, Poor
Key Question 1
McCann et al., 1989
[47]
USAID, Family
Health International,
Wyeth
Cohort
Argentina
N = 5 0 0 h e a l t h y
multiparous women,
after term delivery
1 week PP:
250=LNG (30 mcg)
250=NH methods (54%
IUD)
BF performance
(continuation,
supplementation)
Infant growth (weight,
length, head circumference,
BF outcomes
Median age of
initiation of
supplementation 5.4
for LNG vs.
Strength:
–Su rv i va l ana l y s i s
performed
Weaknesses:
–Only enrolled older,
Level II-2, Poor
Key Question 1
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Table 1 (continued)
Author,
year,
source of support
Study design,
location,
population
Interventions Outcomes,
follow-up duration
Results Strengths/weaknesses Quality grading/
key question
Pharmaceuticals with prior BF
experience,
ages 30–35 years
growth velocity)
Follow-up 9 months
4.6 months for NH
users (pb.05); also
significantly different
on survival analysis
NH users three times
more likely to
discontinue BF
during study period
than LNG users
(22 vs. 7, p value not
reported)
Infant outcomes
No differences
between groups in
infant growth on any
measure
multiparous women
–High loss to follow-up
(55% at 9 months)
–Statistical analysis not
reported on all outcomes
of interest
–Infant health outcomes
collected but not reported
Moggia et al., 1991 [48]
Family Health
International
Cohort
Argentina
N=500 healthy
women with
experience BF,
after term delivery,
ages 18–35 years
(483 in final analysis)
1 week PP:
250=Norgestrel 75 mcg
250=NH methods (75%
IUD)
BF performance
(supplementation)
Infant growth (weight, length,
head circumference)
Infant health (hospitalizations,
minor illnesses, mortality)
Follow-up 6 months
BF outcomes:
More frequent
supplementary feeding
in NH group at months
2 and 3 (pb.05),
otherwise no
difference; no
difference in number of
women supplementing
at any time
Infant outcomes
Growth
No difference in infant
growth
Health
Nodifferences between
groups in
hospitalizations. Minor
illnessesmore common
in NH group (91 NH,
60 POC, pb.01); 3
infant deaths in NH
group, 0 in POP group
Weaknesses:
–No primiparous women
–Baseline differences
between groups
(birthweight lower in
POP group)
–High loss to follow-up
(15% POC, 13% NH
LTFU over 6 months)
Level II-2, Fair
Key Question 1
Shaaban, 1991 [40]
WHO, Population
Council, Rockefeller
Foundation
Cohort
Egypt
Phase 1:
360 healthy women
and their infants
Phase 2:
5th to 7th week PP:
120=LNG implant
120=NET-EN injectable
120=IUD
BF performance (age of
supplementation, age of
weaning)
Infant growth (weight, arm
circumference, skinfold
thickness)
BF outcomes
No differences in
timing or type of
supplementation
IUD users weaned
earliest, followed by
Weaknesses:
–Methodology poorly
described
–Baseline characteristics
not described
–Statistical analyses not
Level II-2, Poor
Key Question 1
234
S.J.
P
hillips
et
al.
/
C
ontraception
94
(2016)
226–252
PVR and Cu-IUD,
results not discussed
here
Infant development
(attainment of milestones)
Follow-up 12 months
LNG implant and
NET-EN (statistics
not reported)
Infant outcomes
Growth
No differences in
infant growth
Development
No difference in
attainment of
milestones
reported for outcomes of
interest
–Percent lost to
follow-up not reported
Pardthaisong, 1992 [29]
Ford Foundation
WHO
FHI
Cohort
Thailand
N=3231 infants with
varying levels of
prenatal and
lactational DMPA
exposure/nonexposure
During lactation (any time,
77% initiated between
months 1 and 3)
857=DMPA only during
lactation (not pregnancy)
1 2 1 5 =DMPA d u r i n g
lactation, some also during
pregnancy
1167=No DMPA
Infant growth (weight, height)
Length of follow-up for
lactationally exposed infants
unclear
Infant outcomes
Growth
Relative risk for score
below −2Z on growth
chart (no exposure as
reference):
1.1 (0.9–1.2)
lactational exposure
only (no prenatal
exposure); 1.2
(1.0–1.3, pb.05)
any lactational
exposure (including
some with prenatal
exposure); RR 1.1
(0.9–1.4) for any
lactational exposure
when adjusted for
potential confounders
Strengths:
–Clear description of
methodology
–Appropriate analytical
methods
Weaknesses:
–Baseline differences
noted between DMPA
users and nonusers
–Unclear length of
follow-up
–Timing and amount of
exposure to DMPA
unclear
–Unexposed may have
been using other
hormonal methods
Level II-2, Poor
Key Question 1
WHO, 1994 [58,59]
WHO
Cohort
Egypt, Iran, Thailand,
Kenya, Chile, Hungary
N=2466 married
women, after term
delivery and their infants
6–8 weeks PP:
4 7 5 = P O P ( L N G o r
lynestrenol)
541=DMPA
121=NET-EN
453=LNG implant
876=NH (IUD, barriers,
sterilization)
BF performance (frequency,
duration exclusive BF)
Infant growth (weight, arm
circumference, skinfold
thickness)
Infant health (mortality)
Infant development (age
passed standard
developmental test)
Follow-up 12 months
BF outcomes:
Frequency and
duration of BF
differed between
sites, but not
between
contraceptive groups
within a site
Infant outcomes
Growth
One site had larger
weight increase in
NET-EN group (6,
12 months) and
DMPA group
(3 months) compared
to NH group
Smaller increase in
arm circumference at
Strengths:
–Large cohort,
multicultural and
multicenter
–Standardized assessment
of development
–Confounders assessed
and controlled for in
analysis
Weaknesses:
–Large differences
between sites for BF
performance and infant
outcomes
–Percent lost to follow-up
not reported
Level II-2, Fair
Key Question 1
(continued on next page)
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Table 1 (continued)
Author,
year,
source of support
Study design,
location,
population
Interventions Outcomes,
follow-up duration
Results Strengths/weaknesses Quality grading/
key question
two sites for POP
group (3 months and
3 and 12 months)
Development
247 comparisons; 32
showed significant
differences: in 20,
infants in
progesterone-only
groups passed tests at
earlier ages, and in 12,
they passed at later
ages.
Mortality
No significant
differences within
sites by method
Abdel-Aleem et al.,
1996 [51]
South-to-South
Cooperation in
Reproductive Health
Cohort
Egypt
N=242 healthy,
exclusively BF
women and their term
infants (mean age
26 years)
2nd PP month:
120=Nomegestrol implant
120=Cu-IUD
BF performance (frequency
of BF, % BF at all and
exclusively at different time
periods)
Infant growth (weight, arm
circumference, skinfold
thickness)
Infant health (frequency of
diarrhea, fever, cough and
mortality)
Follow-up 12 months
BF outcomes
No significant
differences between
groups in BF
frequency,
continuation or
exclusivity
Infant outcomes
Growth
No differences in
infant growth
Health
No significant
differences in health.
7 infants died: 6 in
implant group
(4 gastroenteritis, 1
seizures, 1
p n e u m o n i a ) , 1
(gastroenteritis) in
IUD group (not
significant, pN.05)
Strengths:
–Assessment of infants
was blinded to
contraceptive group
–Power calculations
presented
Weaknesses:
–Underpowered to look
at infant health outcomes
–Percent follow-up not
reported
–Baseline differences
between groups
Level II-2, Fair
Key Question 1
Hannon et al., 1997
[41]
National Institutes of
Health and Thomas
Wilson Sanitorium
Cohort
USA
N=103 women
consecutive, term
deliveries with ability
to follow-up by
At the time of hospital
discharge:
45=DMPA 150 mg
52=NH (unspecified)
BF performance (BF
continuation and exclusivity)
Follow-up 16 weeks
BF outcomes
No difference in
duration of lactation
(median 10.14 weeks
for DMPA vs.
6.57 weeks in NH
Strengths:
Sample selection/
methods clearly
described
Power calculations
performed
Level II-2, Poor
Key Question 1
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telephone users, p=.19)
No difference in time
to supplementation
with formula
Weaknesses:
-Limited duration of
follow-up
-No infant outcomes
-Baseline differences
between groups (DMPA
younger, unmarried)
Diaz et al., 1997 [60]
WHO, Population
council, CONRAD
Cohort with historical
control
Chile
N=662 cohabitating
parous (1–3) women
after term delivery,
ages 18–38 years
57±3 days PP:
117=POP (lynestrenol)
187=PVR
120=LNG implant
122=Copper IUD
236=NH (LAM)
BF performance (duration of
any and exclusive BF)
Infant growth (weight)
Follow-up 6 months
BF outcomes
No difference
between groups for
mean and total
duration of BF
Infant outcomes
No differences in
growth between
groups
Weaknesses:
Historical control
Level II-2, Fair
Key Question 1
Lawrie et al., 1998
[35]
Schering Ltd, Iris
Ellen Hodges Trust
of the University of
the Witwatersrand,
South African
Medical Research
Council,
South African
Institute forMedical
Research
RCT
South Africa
N=166 immediate PP
women ages N19 years
b48 h PP:
85=NET-EN
84=Placebo
All women additionally
used an NH method
BF performance (duration of
any BF, exclusive or partial)
Maternal depression (not
reported here)
BF outcomes
No difference
between groups in
continuation rates at
6 or 12 weeks
Strengths:
–Clear description of
methods
–Enrolled women
regardless of past/current
BF experience
Weaknesses:
–Small sample size
–BF outcomes were
secondary
Level I,
Fair
Key Question 1
Coutinho et al., 1999
[64]
Rockefeller
Foundation
Prospective cohort
Brazil
N=135 women,
18–35 years old after
term health delivery
planning to
breastfeed for
6 months and their
infants
6 weeks PP:
66=Elcometrine implant
69=Cu-IUD
BF performance (any BF at
follow-up time points)
Infant growth (weight, arm
circumference, skinfold
thickness)
Infant development (age
meeting standard milestones,
using developmental tests)
Follow-up 12 months
BF outcomes
Higher rates in
implant group
(95–76%) vs. IUD
(84–57%) at 3,
6 months (pb.05), no
differences at 9,
12 months
Infant outcomes
Growth
No differences
between groups
Development
No differences in age
met developmental
milestones
Strengths:
–Power ca lcu la t ion
performed
–Standardized outcomes
used and described
Weaknesses:
–No control for potential
confounders
Level II-2, Fair
Key Question 1
Diaz et al., 1999 [28]
Population Council
Newly identified
Prospective cohort
Chile
N=108 BF women
planning to continue
to breastfeed
57±3 days PP
29=LNG implant
51=Cu-IUD
28=PVR (results not
reported here)
BF performance (any or
exclusive BF up to 6 months,
no milk supplementation at
12 months)
Infant growth (weight)
BF outcomes
Fully BF month 6:
93% LNG, 86% IUD
(no difference);
Fully BF month 12:
Strengths:
–Clearly described
methods
Weaknesses:
–BF/Infant outcomes
Level II-2, Fair
Key Question 1
(continued on next page)
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Table 1 (continued)
Author,
year,
source of support
Study design,
location,
population
Interventions Outcomes,
follow-up duration
Results Strengths/weaknesses Quality grading/
key question
Follow-up minimum
12 months
4% LNG, 10% IUD
(no difference)
Duration of lactation
15 months LNG,
14 months IUD (no
difference)
Infant outcomes
Growth
No difference
between LNG and
Cu-IUD groups at
month 1, 6 or 12
were secondary
–Length of follow-up
unclear
–Loss to follow-up not
specified
Bjarnadóttir et al.,
2001 [46]
Organon
Cohort
Iceland
N= 83 multiparous
women with prior
experience BF, after
term delivery, ages
18–40 years
28–56 days PP:
42=Desogestrel 75 mg
41=Cu 375 IUD
BF performance (any BF)
Infant growth (length,
weight, head circumference)
Infant health (intercurrent
illness, hospitalizations)
Follow-up 2.5 years
BF outcomes:
No difference in BF
continuation at cycle
4 (5–6 months PP),
but at end cycle 7
(8–9 months PP),
78% in desogestrel
compared with 59%
in IUD group were
still BF (statistics not
reported)
Infant outcomes
Growth
No differences
Health
Temporary breast
enlargement in 2
infants, increased
sweating in 1 infant in
desogestrel group; no
occurrences in IUD
group. No other
differences in health
Strengths:
–Power calculations
provided
–Clearly described
methods
–Long-term follow-up of
exposed infants
Weaknesses:
–Wide variation in
timing of contraceptive
initiation
Level II-2, Fair
Key Question 1
Baheiraei et al., 2001
[68]
Not stated
Prospective cohort
Iran
N=140 women, after
healthy term delivery
6 weeks PP:
5 1=P r o g e s t o g e n - o n l y
(DMPA; POP)
89=NH (IUD, condom,
sterilization)
Infant growth (weight,
length, head circumference)
Follow-up 26 weeks
Infant outcomes
Growth
No differences in
weight or length at
any time; mean head
circumference change
1.42 cm
(progestogen-only)
vs. 1.19 (NH) at 10–
13 weeks (pb.05). No
Weaknesses:
–Contraceptive use/
switching or
formulations are not
stated
–Separate estimates for
different methods not
presented
–Percent lost to
follow-up not reported
Level II-2, Poor
Key Question 1
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differences at other
time points
Massai et al., 2001 [63]
US Agency for
International
Development/UN
Population Fund
Prospective cohort
Chile
N=200 cohabitating
women, after term
delivery; ages18–38 years
55–60 days PP:
100=Nesterone implant
100=Copper IUD
Lactation performance
Infant growth (weight gain)
Follow-up 1 year
BF outcomes
No difference in BF
episodes per day or
length of BF (273 days
implant vs. 263 IUD)
Infant outcomes
Growth
No differences
Strengths:
–Describes
contraceptive
switching and
discontinuation
Weaknesses:
–High discontinuation
(17% in NES group and
22% in IUD group)
Level II-2, Fair
Key Question 1
Halderman and Nelson,
2002 [42]
National Institutes of
Health
Cohort
USA
N = 3 1 9 w om e n ,
primarily Hispanic,
ages 16–49 years
Prior to discharge from
hospital:
102=DMPA
79=LNG implant or POP
138=NH
BF performance (initiation,
continuation, supplementation)
Follow-up 6 weeks
BF outcomes
No difference in BF
initiation
Any BF at 4 weeks:
83.1% NH, 76.7%
POC (p=.022)
Any BF at 2,
6 weeks: No
difference
Exclusivity,
supplementation: No
difference at any time
Weaknesses:
–Short follow-up
–No infant outcomes
–Aggregate data for
methods other than
DMPA
–Differences between
groups at baseline
(DMPA younger, less
parous, less experienced
with BF)
Level II-2, Poor
Key Question 1
Schiappacasse et al.,
2002 [62]
(Some data
originally reported in
Diaz 1985 [61] and
as part of WHO
1994 [58,59])
WHO
Prospective cohort
from 2 previous
studies
Chile
N=442 cohabitating
parous (1–3) women
after term delivery,
ages 18–35 years
55±3 days PP:
220=LNG implant
222=Copper IUD
BF performance (duration)
Infant growth (weight,
height) and health
Follow-up 6 years
BF outcomes
No differences in
m e a n a n d t o t a l
duration; at 12th
month, LNG group
had fewer fully BF
Infant outcomes
Growth
No differences
Health
Higher incidence of
respiratory infection
(colds, bronchitis;
44.3 vs. 37.7/100
infant months,
pb.0001) and skin
conditions (diaper,
allergic and bacterial
dermatitis, prurigo) in
LNG group. Higher
incidence of
urogenital disease
(0.4 vs. 0.2) and
psychomotor
impairment (23 vs.
12) in IUD group.
Strengths
–Information on
contraceptive switching
and discontinuation
–Long-term follow-up
–Adjusted for potential
confounders
–Power calculation for
infant growth
–Blinded assessment of
health
–Ver i f i c a t i on w i t h
hospital records
Weaknesses:
–High loss to f/u over
time (14% of implant
group and 21% of IUD
group)
–No power calculations
for health outcomes
–Confounders for skin
disease not assessed
–Data from infants from
different time periods
–Pollution levels in
Santiago may limit
Level II-2, Fair
Key Question 1
(continued on next page)
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Table 1 (continued)
Author,
year,
source of support
Study design,
location,
population
Interventions Outcomes,
follow-up duration
Results Strengths/weaknesses Quality grading/
key question
Hospitalizations
greater in LNG group
(1% vs. 0.4%, pb.05)
among BF infants; but
higher in IUD group
overall (1.7% vs.
0.6%)
Rates for other
illnesses similar; 1
death in Norplant
group at 7 months for
acute diarrhea and
septicemia
generalizability
Shaamash et al., 2005
[56]
Schering
RCT
Egypt
N=320 women
after term delivery
6–8 weeks PP:
163=LNG-IUD
157=Copper IUD
BF performance (duration,
number of episodes/day,
exclusivity)
Infant growth (weight, length,
skinfold thickness) and
development (age passing
standard developmental tests)
Follow-up 1 year
BF outcomes
No differences in BF
duration (149 vs.
160 days for
LNG-IUD vs.
Cu-IUD) or
exclusivity
Infant outcomes
Growth
No differences
Development
No differences
Strengths:
–Randomized
–Adequate allocation
concealment
–Sample size
calculations
–Standardized infant
development tests
Weaknesses:
–Enrolment and
exclusion criteria not
stated
–Intent-to-treat analysis
and percent loss to
follow-up not reported
–Infant health outcomes
collected but not reported
Level I,
Fair
Key Question 1
Taneepanichskul et
al., 2006 [53]
Reinprayoon et al.,
2000 [52]
Organon
Prospective cohort
Thailand
N=80 women after
term deliveries, ages
18–40 years
28–56 days PP:
42=ETG implant
38=Copper IUD
BF performance (duration)
Infant/child growth (length,
weight) and development
Infant health (intercurrent
illness)
Follow-up 3 years
BF outcomes
Mean duration of BF:
421 days (Implant)
vs. 423 days (IUD),
NS
Infant outcomes
Growth
No differences
between
contraceptive groups
for length, weight or
head circumference
Health
(no statistical
comparisons
Strengths:
–Long-term follow-up of
infants to childhood
Weaknesses:
–No information on
contraceptive switching
or discontinuation
–Methods to assess
psychomotor
development not stated
–Infant illness by
maternal report only
–Response rate for study
inclusion not stated
–Sample size chosen
Level II-2,
Fair
Key Question 1
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reported)
10/42 implant infants
reported skin/
appendages disorders
vs. 6/38 IUD infants;
17/42 implant infants
reported respiratory
system disorders vs.
10/38 IUD infants; 3/
42 implant infants
reported GI disorders
vs. 5/38 IUD infants;
2/42 implant infants
reported neonatal/
infancy disorders vs.
2/38 IUD infants
No differences
reported in adverse
events or
psychomotor
development (N60%
infants in both groups
had resp. disorders,
and N30% in both
groups had skin
disorders)
based on WHO
recommendations for
toxicology, not for BF
or health outcomes
Brito et al., 2009 [20]
FAPESP
CNPq
Newly identified
RCT (open label)
Brazil
N=40 women with
BMIb30, ages 18–
35 years
24–48 h following delivery:
20=Etonorgestrel implant
(ETG)
6 weeks PP:
20=150 mg DMPA
BF performance (duration of
exclusive BF)
Infant growth (weight)
Maternal health (outcomes
not reported here)
Follow-up 12 weeks
BF outcomes
No difference in
exclusive BF between
groups at 6 weeks or
12 weeks: (6 weeks
95% ETG, 85%
DMPA; 12 weeks
85% ETG, 75%
DMPA)
Infant outcomes
Growth
No differences at 6 or
12 weeks
Strengths:
–Randomization
methods appropriate
–Allocation concealment
appropriate
–Methods clearly
described
Weaknesses:
–Short follow-up
–Small sample size with
no power calculations
Level I, Fair
Key Question 2
Chen et al., 2011 [22]
Anonymous
foundation
Newly identified
RCT (open label)
United States
N=96 women
interested in PP IUD
Immediate postplacental:
50=LNG-IUD
6–8 weeks PP (delayed):
46=LNG-IUD
BF performance (initiation,
duration)
Follow-up 6 months
BF outcomes:
Initiation
32/50 (postplacental);
27/46 (delayed) p=.59
Duration
5 weeks
(postplacental);
8.5 weeks (delayed)
p=.06
Any BF at 6 months
Strengths:
–Randomization
methods appropriate
–Allocation concealment
appropriate
–Methods clearly
described
Weaknesses
–6 members of delayed
group got interim DMPA
Level I, Fair
Key Question 2
(continued on next page)
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Table 1 (continued)
Author,
year,
source of support
Study design,
location,
population
Interventions Outcomes,
follow-up duration
Results Strengths/weaknesses Quality grading/
key question
3/50 postplacental,
11/46 delayed p=.02
ExclusiveBFat 6 months
1/50 postplacental, 6/
46 delayed p=.05
prior to LNG-IUD
placement
–Short follow-up
–Very low rates BF in
both groups may limit
generalizability
Gurtcheff et al., 2011
[23]
National Center for
Research Resources
Newly identified
RCT (open label)
United States
N= 69 peripar tum
women desiring ETG
implant
Insertion at 1–3 days PP:
35=ETG implant (early)
4–8 weeks PP
34=ETG implant (standard)
BF performance (time to
lac togenes is s tage II ,
lactation failure, formula
supplementation)
Follow-up 6 months
BF outcomes
Mean time to
lactogenesis stage II
64 h (early); 65 h
(standard)
Lactation failure
1/34 early, 0/35
standard, risk
difference 0.03 (early
vs. standard)
Formula
supplementation
No difference
between groups at
2 weeks, 4–8 weeks,
3 months or 6 months
Strengths:
–Randomization
methods appropriate
–Allocation concealment
appropriate
–Methods clearly
described
–Power calculations
presented
Weaknesses:
–32% (11/34) women
randomized to standard
insertion did not receive
implant; as a result
analyses are per-protocol
Level I, Fair
Key Question 2
Costa et al., 2012 [26]
FAPESP
Newly identified
Cohort
Brazil
N=82 PP women
6 weeks PP:
28=POCs (DMPA, POP,
LNG-IUD)
54=NH (Barrier, LAM, TL,
Cu-IUD)
BF performance (exclusive
and total BF duration)
Follow-up 6 months
BF outcomes
Exclusive:
Mean duration
137 days NH,
113 days POC (p=.143)
Total (any BF):
183 days NH, 183 days
POC (p=.383)
Strengths:
–Included primiparas
–Clear description ofmethods
Weaknesses:
–No separate analysis of
different POCs
–BF outcomes were
secondary outcomes
Level II-2, Fair
Key Question 1
Espey et al., 2012
[21]
ACOG contraceptive
grant and University
of NewMexico
Newly identified
RCT (double blinded)
US
N=127 women ages
15–45 years, planning
to BF and use oral
contraceptives
2 weeks PP:
64=COC (0.35 mg ethinyl
estradiol, 1 mg norethindrone)
65=POP (norethindrone
0.35 mg norethindrone)
BF pe r f o rmance (BF
continuation at 8 weeks,
6 months; supplementation
at 8 weeks)
Infant growth (weight,
length, head circumference)
Follow-up 6 months for BF
outcomes, 2 months for
infant outcomes
BF outcomes:
No difference in
continuation at
8 weeks (64% COC,
63.5% POP) or over
6 months (survival
analysis); no
difference in
supplementation at
8 weeks (percents not
reported)
Infant outcomes
Growth
No difference through
8 weeks
Strengths:
–Included primiparas
–Randomization
methods appropriate
–Allocation concealment
appropriate
–Methods clearly
described
–Double-blinded
–Minimal method
switching
–Loss to follow-up
similar between groups
Weaknesses
–Small sample size
Level I, Fair
Key Question 1
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–Short follow-up for
infant outcomes
Matias et al., 2012 [16]
N I H , F o g a r t y
International Center,
NICHD, UC Davis
Newly identified
Cohort
Peru
n=117
PP women planning
to exclusively
breastfeed
By 72 h
By 1 month PP:
19=DMPA
By 3 months PP:
41=DMPA
By 6 months PP:
45=DMPA
BFperformance (exclusiveBF
at 3 months and 6 months PP)
Follow-up 6 months
BF outcomes:
Women initiating
DMPA after 72H PP
had higher odds of
exclusive BF at
3 months than those
who initiated before
72 h or those who did
not initiate at all
(adjusted OR 6.1, CI
1.7–21.4 —
unpublished data)
Multivariate model:
DMPA use by
3 months associated
with adjusted RR of
exc l u s i ve BF a t
3 months 1.35 (1.1–
1.66)
Strengths:
–Clearly described
methodology
–Appropriate analytic
methods
Weaknesses:
–Unclear when within
the time frame method
was started
–Unclear what methods,
if any, non-were used by
non-DMPA users
Level II-2, Fair
Key Questions 1 and 2
Brownell et al., 2013
[25]
No funding
Newly identified
Cohort (retrospective)
US
N=183 women who
initiated BF
1st 5 days PP:
68=DMPA
115=No DMPA
BF performance (continuation) BF outcomes:
Median duration
DMPA 30 days, no
DMPA 41 days (HR
1.14, nonsignificant)
Continuation at 2 week
No difference
between groups on
survival curve (p=.24)
Continuation at 6 weeks
No difference
Strengths
–Power analysis done
(but post hoc)
–DMPA e x p o s u r e
verified through hospital
records
–Survival analysis
methodology
Weaknesses
–Few women in either
group continued BF after
Level II-2, Fair
Key Question 1
(continued on next page)
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Table 1 (continued)
Author,
year,
source of support
Study design,
location,
population
Interventions Outcomes,
follow-up duration
Results Strengths/weaknesses Quality grading/
key question
between groups (HR
1.22, p=.42)
Insufficient events
after 6 weeks to draw
conclusions
6 weeks
–Unclear if women in
non-DMPA group were
exposed after 5 days to
either DMPA or to other
contraceptives
Bahamondes et al.,
2013 [24]
FAPESP, Conselho
Nacional de Pesquisa
Newly identified
Prospective cohort
Brazil
N= 40 multiparous
women with prior BF
experience
Day 42 PP:
10=COC
10=ETG implant
10=LNG-IUD
10=Cu-IUD
BF performance (duration,
number of episodes/day)
Infant growth (weight,
height, tibial length)
Infant salivary deuterium
(data not presented)
Follow-up 3 weeks (growth
outcomes); 6 months (BF
outcomes)
BF outcomes:
No significant difference
among groups in
continued BF at 6
months (data not shown)
Significantly more BF
episodes day 4 of
study in ETG vs.
Cu-IUD; otherwise no
difference (data not
shown)
Infant outcomes
No significant
difference in weight
or height change from
days 42–63; significant
difference in increase in
tibial length (0.6 cm vs.
1.3 cm) in ETG vs.
Cu-IUD, otherwise no
significant difference
Strengths:
–Frequent data
collection
–Clea r l y de sc r i bed
methodology
Weaknesses:
–Short follow-up (other
than BF duration measure)
–Small sample size with no
power calculations reported
Level II-2, Poor
Key Question 1
Singhal et al., 2014
[27]
Not stated
Newly identified
Prospective cohort
India
N=250 women who
initiated BF
Days 3–10 PP:
150=DMPA (only 100 with
full follow-up)
100=NH
BF performance (duration,
number of episodes/day)
Infant growth (weight,
length)
Infant health (episodes of
diarrhea, URI, fever, rash)
Follow-up 6 months
BF outcomes:
N o s i g n i f i c a n t
difference between
groups in frequency/
con t inued BF a t
6 weeks or 3 or
6 months
Infant outcomes
No significant
differences between
groups in weight or
length gain at any
time point
N o s i g n i f i c a n t
differences between
groups in illnesses
Strengths
–Included primiparas
–DMPA exposure verified
Weaknesses
–High LTFU and no
information provided on
DMPA users who failed
to provide 6 months
follow-up (50/150)
–Comparison group
poorly described; unclear
which NH methods were
used
–No power calculations
reported
Level II-2, Poor
Key Question 1
Abbreviations: ACOG: American College of Obstetrics and Gynecology; BF: breastfeeding; CEBRE: Center for the Study of Reproductive Biology; FAPESP: Fundação de Amparo à Pesquisa do Estado de São
Paulo; NET: norethisterone; NH: nonhormonal; PP: postpartum; TL: tubal ligation.
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245S.J. Phillips et al. / Contraception 94 (2016) 226–252include progestogen-only pills (POPs), progestogen and
progesterone implants, injectables, progesterone rings and
progestogen-releasing intrauterine devices (IUDs). They are
highly effective when used as directed [6].
The use of progestogen-only methods of contraception
[progestogen-only contraceptives (POCs)] during the period of
lactation has raised concerns for negative effects [7]. Proges-
togens could interfere with lactogenesis, especially immediately
postpartum [8], and have been shown to be transferred to breast
milk [9]. Animal data suggest that progesterone receptors are
common in the developing rat forebrain [10]. It is therefore
possible that POCs may affect infant health or development
[11]. The large loading dose of progestogens found in the
injectable depot medroxyprogesterone acetate (DMPA) has
been particularly called into question [7].
This systematic review was conducted for the WHO's
Medical Eligibility Criteria for Contraceptive Use (MEC)
[12] and examines the effects of POCs on outcomes such as
breastfeeding performance and infant growth, development
and health. It updates a previous review from 2010 [13].2. Methods
We followed PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses) guidelines for the
conduct of systematic reviews. [14]
2.1. Key questions
We identified two key questions of interest: (1) Among
breastfeeding women and their infants, was the use of POCs
associated with a difference in breastfeeding or infant
outcomes, compared with nonuse of POCs? (2) Among
breastfeeding women and their infants, was initiation of
POCs before 6 weeks postpartum associated with a
difference in breastfeeding or infant outcomes, compared
initiation of POCs at 6 weeks or later?
2.2. Search strategy
We searched PubMed for relevant articles in all languages
published or in press from database inception through
December 15, 2014 (see Appendix I). We searched reference
lists of relevant articles for additional citations of interest.
We did not consider unpublished studies, abstracts or
dissertations. We had previously contacted one author for
clarification regarding allocation between treatment groups
[15] and contacted another for clarification of method of
analysis and measures of association of interest [16].
2.3. Study selection
We included primary reports of studies of breastfeeding
women who received POCs (oral, injectable, implantable or
hormonal IUDs), as well as progesterone pellets. Studies
assessing progesterone vaginal rings (PVRs) [17] were
excluded as they were reviewed separately [18]. The mainoutcomes were breastfeeding performance and infant health.
Studies that reported solely on self-perceived ability to
breastfeed (without any reporting on duration of breastfeed-
ing), breastfeeding episodes, milk composition or milk
quantity were excluded. Studies that did not specify when
contraceptives were initiated were also excluded. Studies
that compared use of POCs with use of another type of
hormonal contraceptive were considered indirect evidence.
We included trials, cohort and case–control studies and
excluded cross-sectional and noncomparative studies.
2.4. Study quality assessment
Two authors assessed the quality of each study (SP and
NT) using the United States Preventive Services Task Force
evidence grading system [19].
2.5. Data synthesis
We used a standard data abstraction template to
systematically assess and summarize the evidence. Because
many studies and recommendations separate results by the
use of contraception before and after 6 weeks postpartum,
we structured this report similarly. Summary odds ratios
were not calculated, given the heterogeneity of interventions,
results and nonquantifiable outcomes reported.3. Results
The literature search yielded 848 articles; 771 were
excluded on title and abstract review and 28 were excluded
after full-text review, leaving 49 reports meeting inclusion
criteria. Since this review was last updated in 2008 [13], four
new randomized controlled trials (RCTs) [20–23] and five
new observational studies were published [16,24–27], and
an additional five observational studies that were not
included in the 2008 review were identified [28–32], for a
total of eight reports of RCTs and 41 reports of nonrando-
mized clinical trials or observational studies for review
(Table 1). These 49 articles reported on 47 different studies
investigating the use of POCs in breastfeeding women and
reported clinically relevant outcomes of infant growth, health
or breastfeeding performance.
Results for Key Question One, then for Key Question
Two, are presented by study design and by time of
contraceptive initiation: less than 6 weeks or greater than
or equal to 6 weeks postpartum. Newly identified studies are
presented first, followed by a brief summary of findings from
the previous review. Nonrandomized clinical trials are
presented together with observational data.
3.1. Key Question One, initiation at less than 6 weeks
postpartum: Lactation performance
3.1.1. Randomized clinical trials
Four RCTs [21,33–35] investigated POC initiation within
6 weeks postpartum. A new RCT provides indirect evidence:
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either POPs or combined oral contraceptives (COCs), started
2 weeks postpartum [21]. No difference was noted between
groups in breastfeeding continuation or supplementation
over 6 months.
Three RCTs were included in the previous review. In one,
fewer levonorgestrel (LNG) IUD users were breastfeeding
than copper (Cu) IUD users at 75 days; this difference
disappeared at 6 months [34]. Mean duration of breastfeed-
ing was similar. Another investigating the use of norethin-
drone compared with placebo found no difference between
groups in breastfeeding initiation [33]. A third found no
difference in breastfeeding outcomes over 12 weeks be-
tween women who received injectable norethisterone
enanthate (NET-EN) or placebo [35].
3.1.2. Nonrandomized clinical trials and observational studies
3.1.2.1. Injectables. In 11 nonrandomized clinical trials
and observational studies, four of which are newly included
since the last review [16,25,27,31], progestogen-only
injectables (POIs) (either DMPA or NET-EN) were initiated
in the first 6 weeks postpartum; most of these found either no
effect on breastfeeding outcomes or improved outcomes
among DMPA users. In one new prospective cohort study,
women initiated DMPA or a nonhormonal method postpar-
tum; no difference in breastfeeding frequency or continua-
tion was observed at 6 weeks or at 3 or 6 months [27]. A
second prospective cohort study found that women who
initiated DMPA after 72 h were more likely to exclusively
breastfeed at 3 months than those who either did not initiate
or initiated early [16]. No differences emerged in exclusive
breastfeeding to 6 months for those who did not initiate
DMPA compared with those who initiated by 3 or 6 months.
A third retrospective cohort study found no significant
differences in duration or continuation of breastfeeding
through 6 weeks between women who initiated DMPA
before 5 days postpartum compared with those who did not
[25]. The fourth new study prospectively investigated the use
of DMPA compared with use of other contraceptive methods
[31]. Most of the women studied received DMPA within the
first 3 months postpartum. Those who received DMPA were
more likely to be fully breastfeeding at 3 and 6 months
postpartum and were more likely to continue breastfeeding
through 12 and 18 months. Of women who received DMPA
in the first 3 months, 35% were still breastfeeding at
12 months compared with 67% of those who received
DMPA after 3 months.
The remaining studies were included previously. One
found that no women using NET-EN, DMPA or nonhor-
monal methods supplemented breastfeeding in the 6-month
study period [36]. Another found that women using DMPA
breastfed for longer than a historical control group, although
no difference was noted compared with IUD users [37]. Two
other studies similarly found longer duration of breastfeed-
ing among women using DMPA compared with nonhor-monal methods [38,39]. Another found that NET-EN
and (presumably nonhormonal) IUD users had no difference
in time to first supplementary feeding, but infants of
IUD users weaned earlier [40]. Mothers who received
either DMPA or a nonhormonal method at hospital discharge
had no differences in breastfeeding exclusivity, supplemen-
tation or duration [41]. Finally, when DMPA initiated at
hospital discharge was compared with nonhormonal method
use, no differences were found in breastfeeding at 2 or
6 weeks, although fewer DMPA users were breastfeeding at
4 weeks [42].
3.1.2.2. POPs. Eight observational studies assessed the
use of POPs in the first 6 weeks postpartum; all were
included in the previous review and found either no
differences between POP users and nonusers or improved
breastfeeding outcomes with POP use. In a nonrandomized
trial, POP users initiated breastfeeding earlier than placebo
users [43]. Other studies found no difference in breastfeeding
duration for POP users compared with historical controls
[37] or compared with nonhormonal users [39,44], while two
found longer breastfeeding duration among POP users
compared with historical controls [45] or IUD users [46].
Finally, two studies found less supplementation among POP
users than nonhormonal users [47,48].
3.1.2.3. Implants. Five observational studies, all in the
previous review, largely found no difference in outcomes
when assessing the impact of implants in the first 6 weeks
postpartum. Women using a norethindrone implant were
more likely to supplement breastfeeding at 3 months than
those using condoms, but no differences were noted at any
other time through 6 months or in the mean duration of
breastfeeding [49]. Two studies found no difference in
supplementation comparing LNG implant with IUD users
[40,50]; one of these also found no difference in breastfeed-
ing duration [50]. Users of nomegestrol implants compared
with IUD users similarly had no difference in time of
weaning or breastfeeding rates through 12 months [51].
Finally, breastfeeding duration did not differ between users
of an etonogestrel (ETG) implant compared with Cu-IUD
users over 3 years [52,53].
3.1.2.4. Multiple POCs. One study, included previously,
assessed users of the LNG implant or POPs (analyzed
together) and found no differences in breastfeeding initiation
or exclusivity, although POC users were less likely to be
breastfeeding than nonhormonal users at one of three time
points [42].
3.1.2.5. Nonorally available progestogens. Progesterone,
unlike progestogens, is not absorbable orally; therefore, use
during breastfeeding is believed to be safe for a neonate. As
it is absorbed by the mother, it could impact breastfeeding.
Two studies examined the use of progesterone pellets in the
first 6 weeks postpartum; both were included in the previous
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breastfeeding at 6 months [54] or at 6 and 12 months [55],
compared with Cu-IUD use.
3.2. Initiation at≥6 weeks postpartum: Lactation performance
One RCT and 13 observational studies (four newly
identified [24,26,28,30]) evaluated the use of POCs initiated
6 weeks postpartum or more. None of these reported
negative impacts on breastfeeding outcomes among POC
users compared with nonusers, with the exception of one
observational study that found that the average age of
supplementation was younger among POP users compared
with IUD users [30].
3.2.1. RCTs
OneRCT, previously reviewed, found no difference between
Cu-IUD and LNG-IUD users in duration of breastfeeding or
supplementation at 6–8 weeks postpartum [56].
3.2.2. Observational studies
3.2.2.1. Injectables. Three observational studies (one new)
were identified. The new study did not find supplementation
among infants of mothers receiving injectables nor among those
who received nomethod [36]. Among the studies included in the
previous review, one found no difference between DMPA and
nonhormonal users in breastfeeding discontinuation or initiation
of complementary foods [57]. Another found no difference in
breastfeeding duration within study sites between DMPA and
NET-EN users, compared with nonhormonal method users,
although differences were seen between sites [58,59].
3.2.2.2. POPs. Four studies (one new) assessed the impact
of POPs on breastfeeding outcomes. In the new study, a
nonrandomized trial [30], women used POPs, a Cu-IUD plus
placebo pill or one of several combined hormonal methods.
The average age of supplementation was lower in the POP
group compared with the IUD group (11.2 vs. 15 weeks),
although statistical comparisons were not reported. Among
the studies included in the prior review, one found no
difference in complementary feeding or breastfeeding
continuation up to 24 weeks when comparing POP users
with nonhormonal users [57]. Two others found no
difference in breastfeeding duration between POP and
nonhormonal users [58–60].
3.2.2.3. Implants and hormonal IUDs. Six studies, two of
which are new, assessed the impact of implant or hormonal
IUD use on breastfeeding outcomes; none found differences
between groups. One new study assessed the effect of both
the ETG implant and the LNG-IUD compared with Cu-IUD
and found no differences between groups in mean duration
of breastfeeding at 6 months [24]. The other new study
included LNG implant and Cu-IUD users and found no
difference in the percentage of fully breastfeeding at month 6
or 12 and no difference in breastfeeding duration [28].In one of the previously reviewed studies, women who
received a norethindrone implant were similar to condom
users in supplementation and breastfeeding continuation to
8 months [49]. In three studies of women who initiated the
LNG implant, similar duration of breastfeeding was seen
among both hormonal and nonhormonal users [58–62].
3.2.2.4. Multiple progestogen-only methods. One new
study assessed the impact of multiple POCs without
presenting outcomes separately by method. This prospective
cohort found no difference in duration of breastfeeding
between users of POCs and nonhormonal methods over
6 months [26].
3.2.2.5. Nonorally available progestogens. Three studies,
none new, assessed the impact of nonorally available
progestogens (progesterone pellets and nesterone or elcome-
trine implants) on breastfeeding outcomes. In two of these,
breastfeeding duration was similar between women using
progesterone pellets [54] or a nesterone implant [63],
compared with Cu-IUD. Elcometrine implant users had a
higher rate of breastfeeding at 3 and 6 months and similar
rates at 9–12 months compared with Cu-IUD users [64].
3.3. Initiation less than 6 weeks postpartum: Infant outcomes
Thirty-seven studies (four RCTs, 32 observational studies
and one cohort study with a nested RCT) were identified,
including many of the studies previously described.
Although some studies found differences in growth, health
or development at some individual time points, most
demonstrated no adverse impact of POCs.
3.3.1. RCTs
Three trials were identified. One of these studies is new
and provides indirect evidence; the other two were included
in the previous review. In the new study, women initiated
either POPs or COCs at 2 weeks postpartum; no differences
emerged in infant weight, length or head circumference
through 8 weeks [21]. In a study of POPs or placebo, no
differences were reported for infant weight gain at 14 days
[33]. Similarly, infants of LNG-IUD users had similar
weight, height and health through 12 months compared with
Cu-IUD users [34].
3.3.2. Observational studies
3.3.2.1. Injectables. Seven observational studies, three
newly identified [27,29,32], assessed infant outcomes after
initiation of POIs; all either found no detrimental effect or a
protective effect of injectables on infant growth and health. A
new cohort study of 250 women found no differences in
infant growth or reports of illness up to 6 months when
comparing users of DMPA initiated within 10 days
postpartum with users of nonhormonal methods [27].
Another newly identified cohort study found no difference
in infant weight gain up to 46 months between infants whose
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and those who did not receive DMPA prior to 9 months
postpartum [32]. No significant differences were found
between groups in infant infections, although a subgroup that
received DMPA within 2 days postpartum had a 75% higher
incidence than the other groups (statistics not reported).
Another cohort study included infants who were exposed to
DMPA during breastfeeding (but not during their mother's
pregnancy), during both pregnancy and breastfeeding or not
at all [29]. Infants who were exposed only during
breastfeeding were no more likely than the unexposed to
have a height or weight over two standard deviations below
the mean. Infants exposed to DMPA during breastfeeding
(including those exposed during pregnancy) were more likely
to have short stature; this difference was no longer significant
after adjusting for socioeconomic factors and no effect on
weight was seen. Follow-up period was unspecified.
The remaining four studies were included in the previous
review. In one, infant weight gain was the same for NET-EN,
DMPA and Cu-IUD users up to month 3, after which weight
gain was greater in both the DMPA and NET-EN groups
[36]. No physical, mental or radiological differences were
seen through 18 months. Another study found no effect
of maternal DMPA use on infant weight, development or
health compared with nonhormonal method use through
3–6 years of follow-up [38]. One child death was reported
in the nonhormonal group, and none was reported in the
DMPA group. In another study, infants had no adverse
effects with maternal NET-EN use through 30 months of age
when compared with nonhormonal method use; specific
outcomes were not provided [39]. The fourth study found no
difference in growth or development among infants of
NET-EN users compared with infants of Cu-IUD users over
12 months [40].
3.3.2.2. POPs. Six observational studies or nonrando-
mized trials, none new in this review, assessed infant
outcomes associated with POP use; most found no adverse
effects. In one study, infants of women using POPs had
greater weight increase than placebo users at day 14 [43].
Another study found no difference in urinary FSH, LH or
testosterone among male infants of POP users compared
with users of no method at 4 weeks [65]. Another study
found no adverse effects of POPs up to an average of
4.5 years of age, compared with infants of women who used
the lactational amenorrhea method (LAM) or the IUD
(presumably nonhormonal) [39]. Two studies found no
growth differences between infants of mothers using POPs
compared with nonhormonal users [47,48]; one of these also
found no difference in hospitalizations [47], while the other
found more frequent minor illnesses and greater mortality (3
vs. 0 deaths) among children of mothers who used
nonhormonal methods [48]. Finally, infants of desogestrel
users had temporary breast enlargement (2 infants) and
perceived increased sweating (1 infant), compared with no
adverse effects among infants of Cu-IUD users [46].Follow-up through 2.5 years revealed no clinically relevant
effects of desogestrel on the growth or health of the infants.
3.3.2.3. Implants. Eight studies that assessed the impact of
implants were included, none of which is new; generally no
adverse effects were reported. In one study, infant weight
was no different between norethindrone implant and barrier
method users [49]. Another found no health or serum
immunoglobulin differences between infants of LNG
implant and nonhormonal users [66] and another found no
differences in mean FSH, LH or testosterone [65]. One study
found slower weight gain in infants of LNG implant users up
to 3 months, compared with Cu-IUD users. This difference
disappeared at 4–6 months; however, length increased less
among infants of LNG users compared with Cu-IUD users
[50]. No differences in morbidity were reported. In another
study, infant lengths did not differ and weight was greater
among infants of LNG implant users [67], and in a third, no
differences were found between implant users and nonhor-
monal users in growth or development [40]. A study of the
nomegestrol implant compared with Cu-IUD found no
difference in growth or health; greater infant mortality was
seen in the implant group (six deaths from gastroenteritis,
seizures and pneumonia, compared with one death from
gastroenteritis in the Cu-IUD group) but was not statistically
significant [51]. Finally, a study of ETG implants compared
with the Cu-IUD found no differences in infant growth,
adverse events, respiratory or skin disorders or developmen-
tal scores [52,53].
3.3.2.4. Nonorally available progestogens. Two studies
reported no difference in infant growth or health
comparing progesterone pellet users with placebo or Cu-
IUD users [54,55].
3.4. Initiation at ≥6 weeks: Infant outcomes
Most of the studies described above also reported on
infant outcomes. The majority found no significant differ-
ences between infants of POC users and nonhormonal
method users, although differences in both directions were
noted in some comparisons.
3.4.1. RCTs
Two RCTs (neither new) investigated the effect of POC
initiation after 6 weeks postpartum. In both, no differences
in infant growth or development were seen between users of
the LNG-IUD compared with the Cu-IUD through 1 year
[56] or between users of POPs or DMPA compared with
nonhormonal method users through 24 weeks [57].
3.4.2. Observational studies
3.4.2.1. Injectables. Three observational studies (none
new) assessed the impact of maternal use of POIs initiated
at 6 weeks postpartum or later; none is new. One found
increased weight gain among infants of DMPA and NET-EN
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physical, mental or radiological differences over 18 months
[36]. Another similarly found no difference in mean weight
between DMPA users and nonhormonal users through
24 months [57]. Another study showed more weight gain
among infants of DMPA and NET-EN users at some time
points (3 and 12 months) and no difference at others (6 and
9 months). The majority of comparisons in developmental
tests were similar, although some tests favored nonhormonal
methods and others favored DMPA or NET-EN [58,59].
3.4.2.2. POPs. Four studies, one new [30], assessed the
impact of POPs. The new study found no difference in infant
growth between those whose mothers used a POP compared
with those whose mothers used an IUD plus placebo pill up
to 32 weeks [30]. In the other three studies, one found
smaller increase in arm circumference at two sites among
infants of POP users compared with nonhormonal users but
found no difference for other growth measures or for the
majority of developmental test results [58,59]. The second
found no differences in infant weight gain over 6 months
when comparing infants of POC users with those of users of
multiple other hormonal and nonhormonal methods [60].
The third found no difference in infant growth (length,
weight, arm circumference) among infants of women using
POPs compared with those using nonhormonal methods [57]
3.4.2.3. Implants/hormonal IUDs. Six studies, two new
[24,28], assessed infants whose mothers initiated progesto-
gen-only implants or hormonal IUDs. In one new study,
women initiated the ETG implant or LNG-IUD 6 weeks
postpartum; no difference was found in infant weight or
height through 6 months, although infants in the implant
group had less increase in tibial length than infants in the
Cu-IUD group [24]. The other found no differences over
12 months in infant weight between users of the implant and
users of the Cu-IUD initiated at 8 weeks [28].
The remaining four studies were included previously. In
one, infants of women who used a norethindrone implant had
no differences in weight gain compared with those who used
nonhormonal implants [49]. Likewise infants of LNG
implant users had similar growth and development compared
with nonhormonal users, although a few differences were
noted in some of the multiple developmental tests [58,59]. In
two studies of LNG implant use compared with nonhor-
monal methods, no differences were noted between groups
in infant weight gain [60,62], although in one of the studies,
a higher incidence of respiratory infections and skin
conditions was noted among infants whose mothers used
an LNG implant [62]; more urologic and neurological
conditions occurred among infants of Cu-IUD users.
3.4.2.4. Multiple progestogen-only methods. One study
(not new) included infants of mothers using various POCs
and found that infant growth was generally the same between
POC and nonhormonal users [68].3.4.2.5. Nonorally available progestogens. Three studies
reported on infant outcomes of mothers using nonorally
available progestogens, none new. Infant growth was no
different in users of nesterone pellets compared with
nonhormonal methods [63]; neither infant growth nor health
was different between users of progesterone pellets and users
of nonhormonal methods [54]. Similarly, there was no
difference in infant growth or development between infants
of users of nesterone implants and Cu-IUD users [64].
3.5. Key Question Two: Early versus delayed initiation
In total, eight studies address the effect of initiation of
POCs before 6 weeks postpartum compared with later
initiation, of which five are new [16,20,22,23,32]. The
majority found no effect on breastfeeding or infant
outcomes, although one RCT found that more women
continued breastfeeding at 6 months in the later initiation
group [22] and another found more infections in infants of
DMPA users [32].
3.5.1. Breastfeeding outcomes: RCTs and observational
studies
Six of the studies assessed breastfeeding outcomes when
POCs were initiated early or late postpartum (three RCTs,
three observational). All three RCTs and one of the
observational studies are new. One RCT compared women
using ETG implants immediately postpartum versus DMPA
initiated at 6 weeks [20]. No differences were seen between
groups in the percentage of women exclusively breastfeeding
at 6 or 12 weeks. Another RCT compared postplacental
placement of LNG-IUD with delayed placement at 6–
8 weeks and found no difference in breastfeeding initiation
between groups or in breastfeeding continuation at 6–
8 weeks; women in the delayed group were more likely to be
breastfeeding at 6 months [22]. A final study compared
women randomly assigned to the ETG implant either 1–
3 days postpartum or at 4–8 weeks postpartum and found no
significant difference in breastfeeding outcomes [23].
One new observational study found that women who
initiated DMPA after 72 h postpartum were more likely to be
breastfeeding at 3 months than those who initiated before
72 h or who did not use DMPA [16]. In the other
observational studies, norethindrone implant initiated early
compared with delayed was not associated with differences
in supplementary feeding or continuation of breastfeeding
[49], and women who initiated progesterone pellets later
were more likely to be supplementing breastfeeding than
those who initiated early [54].
3.5.2. Infant outcomes: Observational studies
No RCTs and four observational studies (one new [32])
were identified for infant outcomes. The new study found
that women who received DMPA within 48 h postpartum
reported a higher incidence of infectious diseases in their
infants than those who initiated DMPA later or not at all [32].
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DMPA or NET-EN was not associated with any differences
in growth, development or health [36], nor was early versus
delayed norethindrone associated with growth differences
[49]. Use of progesterone pellets was not associated with any
differences in growth, development or health [54].4. Discussion
Overall, evidence from 49 articles reporting on 47 studies
on use of POCs during breastfeeding is of poor to fair
methodological quality. Of the 14 studies that were newly
included in this review, four were older studies [29–32] of
poor quality and one was published in 1999 and of fair
quality [28]. None of these older studies showed any
negative effect of use of POCs on breastfeeding or infant
outcomes. Of the nine studies that were published since the
last review, four were RCTs. One of the four trials suggested
that early, compared with delayed, postpartum initiation of
the LNG-IUD was associated with shorter breastfeeding
duration and less breastfeeding exclusivity at 6 months [22].
However, two other RCTs found no differences [20,23]. The
fourth new trial provides indirect evidence demonstrating no
difference in outcomes between POPs compared with COCs
[21]. Among the newly identified observational studies,
findings were generally consistent with the observational
studies in the previous review, with no adverse effects noted
on breastfeeding or infant outcomes.
Exogenous administration of POCs could theoretically
inhibit breastfeeding [69]; however, the evidence in this
review does not generally support a negative impact on
breastfeeding outcomes. Studies examining the initiation of
POCs among postpartum women overall demonstrated no
adverse effects on measures of breastfeeding success, such as
duration of breastfeeding or time to supplementation,
although a few reported differences in both positive and
negative directions at individual time points. The prepon-
derance of the evidence points toward no deleterious impact
of POCs on breastfeeding success, although further study is
warranted to examine the impact of immediate postpartum
placement of the LNG-IUD.
Theoretical concerns also have been raised regarding the
impact of exposure to progestogens on neonates, particularly
in the first 6 weeks of life [7]. Studies identified in this
review showed no consistent adverse effects of exposure to
progestogens through breast milk on infant health outcomes
such as growth, development and health through the first few
years of life. We identified no data to inform a conclusion on
longer-term effects and any such effects remain unknown.
The PVR was not addressed in this review. A recent
review concluded that PVR use among breastfeeding women
did not affect breastfeeding performance or infant growth
during the first year postpartum [18].
Our ability to draw firm conclusions is limited as most
studies are observational, have lacked clear definitions ofbreastfeeding patterns and failed to control for potential
confounders [70]. Many did not provide information key to
determining their quality and did not perform tests of
significance. Some were not informative to our cutoff point
of 6 weeks as participants initiated both before 6 weeks and
after. Initiation before 6 weeks ranged from immediately
postpartum to nearly 42 days.
In 2014, the WHO Expert Working Group reviewed this
evidence to evaluate medical eligibility criteria for the use of
POCs among breastfeeding women. All of the above-
mentioned studies were reviewed with the exception of
one, which was identified after the meeting and found no
deleterious effects of POCs [27]. The findings of this
systematic review were incorporated into the recent update
of the MEC [71].5. Conclusion
Consistent evidence by multiple measures of successful
breastfeeding, largely from fair or poor quality observational
studies, suggests that POCs, when used by lactating women,
do not compromise a woman's ability to breastfeed.
Evidence that POCs do not adversely affect infant growth,
health or development during the first year postpartum is
generally consistent across observational and randomized
studies. Further research is necessary to determine any
effects on child health or development beyond the first year.
Evidence newly added to this review is largely consistent
with the previous evidence.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.contraception.2015.09.010.
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